NCT03054363: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

NCT03054363
Breast Cancer Type: HER2+
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 100 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must also be either ER++ or PR+
Exclusions: Subjects with previously treated progressing brain metastases; stable brain metastases allowed- check trial for details
https://ClinicalTrials.gov/show/NCT03054363

Comments are closed.

Up ↑